December 15, 2020. FDA should not approve this new indication until an adequate number of Black patients have been studied and the results are conclusive for all patients.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
NCHR’s Comments to EPA’s Children’s Health Protection Advisory Committee
We urge the EPA to dedicate more resources towards studying the chemicals and metals contained in artificial turf and playground surfaces, and focus on ensuring that the materials used are safe for children who will be frequently exposed and/or who might be particularly vulnerable because of other health conditions and other exposures.
Read More »Testimony of Dr. Diana Zuckerman of NCHR before the FDA Advisory Committee on Pfizer COVID Vaccine
We need longer-term data on the Pfizer COVID-19 vaccine to fully understand if benefits outweigh the risks for frail patients and all races/ethnicities, and for everyone else as well. It is essential that FDA ensure the continuation of the randomized controlled trial.
Read More »NCHR’s Public Comments on Breast Cancer Treatment for Premenopausal Women
We strongly recommend that clinical trials on breast cancer treatments should include pre-menopausal women.
Read More »Public Comments Regarding ACIP Meeting on December 1, 2020
We are concerned about the lack of data on the vaccines in patients living in long-term care facilities, or any patients over 65 years of age.
Read More »